Synthesis of novel kaurane analogues , their preparation, and their uses in cardiac protection against ischemia, hypertrophy and chemotherapy induced cardiomyopathy as well as cerebral ischemia.

##STR00001## Wherein R.sup.1: formyl, carboxylic acid (carboxyl), salt of carboxylic acid R.sup.2: oxygen, C-16 ketone to hydroxyl

The present invention provides a method for producing a bifunctional compound having a norbornane skeleton, the method comprising a step of hydroformylating a compound having an olefin with carbon monoxide and hydrogen, wherein the molar ratio of the carbon monoxide to the hydrogen during the reaction is 55/45 or more and 95/5 or less in the hydroformylating step.

Embodiments in accordance with the present invention encompass compositions encompassing a latent organo-ruthenium compound and a pyridine compound along with one or more monomers which undergo ring open metathesis polymerization (ROMP) when said composition is exposed to suitable actinic radiation to form a substantially transparent film. Surprisingly, the compositions are very stable at ambient conditions to temperatures up to 80° C. for several days and undergo mass polymerization when subject only to actinic radiation. Accordingly, compositions of this invention are useful in various opto-electronic applications, including as 3D printing materials, coatings, encapsulants, fillers, leveling agents, among others.

The present disclosure relates to a spiro compound and application thereof. The spiro compound has a structure as shown in a formula (1). The material provided in the present disclosure has advantages such as high optical and electrical stability, low sublimation temperature, low drive current, low lateral mobility of carriers, high luminous efficiency, and long service life of a device, and can be used in an organic electroluminescent device. In particular, the compound has the possibility of being applied in the AMOLED industry as a hole injection or transport material.

The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

The present specification relates to a heterocyclic compound represented by Chemical Formula 1 and an organic light emitting device including the same.

The present invention is a sulfonium-salt-type polymerizable monomer represented by the following formula (1),

##STR00001## wherein “p” represents an integer of 1 to 3; R.sup.11 represents a C1-20 hydrocarbyl group; R.sup.f represents a fluorine atom or a fluorine-atom-containing C1-6 group selected from alkyl, alkoxy, and sulfide; “q” represents an integer of 1 to 4; R.sup.ALU represents an acid-labile group; “r” represents an integer of 1 to 4; R.sup.12 represents a C1-20 hydrocarbyl group; “s” represents an integer of 0 to 4; “t” represents an integer of 0 to 2; R.sup.f and —O—R.sup.ALU are bonded to adjacent carbon atoms; and A-X.sup.− represents a non-nucleophilic counterion having a polymerizable group A. This provides: a monomer to yield a polymer; the polymer contained in a resist composition; the composition having excellent solvent-solubility, sensitivity, contrast, and lithographic performance, and hardly causing pattern collapse even with fine patterning; and a patterning process using the composition.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present disclosure relates to a novel compound represented by Chemical Formula 1 and an organic light emitting device using the same. The compound is used as a material of an organic material layer of the organic light emitting device. ##STR00001##

The present invention relates to diterpene compounds of general formula (I) capable of contrasting the antibiotic-resistance mediated by the ArnT enzyme, to their use as a medicament, in particular for use as an adjuvant of an antibiotic therapy in the treatment of antibiotic-resistant bacterial infections. The invention relates also to associations of one or more of the compounds of formula (I) with at least another active ingredient, in particular an antibacterial agent and/or an antibiotic, and compositions comprising one or more compounds of formula (I) or the association according to the present invention and at least one pharmaceutically acceptable excipient and/or carrier as well as to products, in particular medical devices, comprising at least a compound, an association or a composition according to the present invention. Moreover, the invention relates to the use of compounds of formula (I) to sensitize a bacterium to an antibacterial agent or an antibiotic, for example, colistin (polymyxin E) or polymyxin B and to an in vivo or in vitro method for sensitizing a bacterium to an antibacterial agent or an antibiotic comprising the exposure of said bacterium to one or more compounds of formula (I) together with colistin.